Canada Markets open in 2 hrs 54 mins

AIM ImmunoTech Inc. (AIM)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
1.41000.0000 (0.00%)
At close: 04:00PM EST
1.4200 +0.01 (+0.71%)
Pre-Market: 05:53AM EST
Full screen
Trade prices are not sourced from all markets
Previous Close1.4100
Bid1.3500 x 800
Ask1.5400 x 1100
Day's Range1.3510 - 1.4400
52 Week Range1.1100 - 3.0600
Avg. Volume345,722
Market Cap67.445M
Beta (5Y Monthly)-0.83
PE Ratio (TTM)N/A
EPS (TTM)-5.8730
Earnings DateAug. 12, 2021 - Aug. 16, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.67
  • GlobeNewswire

    AIM ImmunoTech Provides Third Quarter 2021 Business Update

    OCALA, Fla., Nov. 16, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the third quarter ended September 30, 2021 and provides a business update. Third Quarter 2021 Financial Highlights: As of September 30, 2021, AIM had cash, cash equivalents and marketable securities of $53.7 million, compared to $54.4 million as of December 31, 2020. Research and development expenses for the three months ended September 30, 2021 were $2.0 million, compared to $

  • GlobeNewswire

    AIM ImmunoTech Submits IND and Accompanying Fast Track Application for Phase 2 Trial of Ampligen in Patients with Locally Advanced or Metastatic Late-Stage Pancreatic Cancer

    OCALA, Fla., Oct. 19, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has submitted an Investigational New Drug application (IND) and an accompanying application for Fast Track status with the U.S. Food and Drug Administration (FDA) for a planned Phase 2 study of the company’s drug Ampligen as a therapy for locally advanced or metastatic late-stage pancreatic cancer. The planned AMP-270 clinical trial of approximately 250 subjects will be a Phase 2, rand

  • GlobeNewswire

    AIM ImmunoTech Publishes Phase 1 Clinical Study Data Supporting the Safety of Ampligen as an Intranasal Therapy

    CHDR Table 1 CHDR Table 1 CHDR Table 2 CHDR Table 2 OCALA, Fla., Oct. 06, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today released detailed safety data from a Phase 1 clinical study which supports the company’s belief that its drug Ampligen has significant potential as an intranasal therapeutic for COVID-19. AIM previously announced that the study to assess the safety, tolerability and biological activity of Ampligen as a potential intranasal therapy was completed, and th